GW685698
Showing 1 - 25 of 56
Pulmonary Disease, Chronic Obstructive Trial in United States (Batefenterol + Fluticasone Furoate, Placebo, Albuterol)
Completed
- Pulmonary Disease, Chronic Obstructive
- Batefenterol + Fluticasone Furoate
- +2 more
-
Phoenix, Arizona
- +9 more
Jul 13, 2020
Rhinitis, Allergic, Seasonal Trial (GW685698X Aqueous Nasal Spray)
Completed
- Rhinitis, Allergic, Seasonal
- GW685698X Aqueous Nasal Spray
-
,GSK Investigational Site
Aug 30, 2018
Arnuity® Ellipta® Drug Use Investigation
Completed
- Asthma
- Arnuity Ellipta
-
Hokkaido, Japan
- +1 more
Apr 22, 2021
Rhinitis, Allergic, Seasonal Trial (GW685698)
Completed
- Rhinitis, Allergic, Seasonal
- GW685698
-
,GSK Investigational Site
Aug 30, 2018
Asthma Trial in Worldwide (FF/VI via ELLIPTA DPI, FF via ELLIPTA DPI)
Completed
- Asthma
- FF/VI via ELLIPTA DPI
- FF via ELLIPTA DPI
-
Hoover, Alabama
- +183 more
Sep 12, 2022
Asthma Trial in Worldwide (GW685698X 200mcg,GW685698X 200mcg and 400mcg)
Completed
- Asthma
- GW685698X 200mcg,GW685698X 200mcg and 400mcg
-
Fullerton, California
- +81 more
Jan 18, 2018
Asthma Trial in Wellington (GW685698X, GW685698X containing magnesium stearate)
Completed
- Asthma
- GW685698X
- GW685698X containing magnesium stearate
-
Wellington, New ZealandGSK Investigational Site
Aug 3, 2017
Asthma Trial in Melbourne (GW685698X, Placebo)
Completed
- Asthma
- GW685698X
- Placebo
-
Melbourne, Victoria, AustraliaGSK Investigational Site
Aug 2, 2017
Asthma Trial in United Kingdom (fluticasone furoate + vilanterol, inhaled corticosteroid with or without a long acting
Completed
- Asthma
- fluticasone furoate + vilanterol
- inhaled corticosteroid with or without a long acting beta2-agonist
-
Altrincham, Cheshire, United Kingdom
- +179 more
Jul 26, 2018
Asthma Trial in Randwick, Sydney (GW685698X & GW642444M)
Completed
- Asthma
- GW685698X & GW642444M
-
Randwick, Sydney, New South Wales, AustraliaGSK Investigational Site
Aug 2, 2017
Pulmonary Disease, Chronic Obstructive Trial in Worldwide (fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25
Completed
- Pulmonary Disease, Chronic Obstructive
- fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Novel Dry Powder Inhaler (NDPI)
- Tiotropium
-
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
- +54 more
Jan 18, 2018
Asthma Trial in Randwick (Fluticasone foroate/ vilanterol, Fluticasone foroate, Vilanterol)
Completed
- Asthma
- Fluticasone foroate/ vilanterol
- +3 more
-
Randwick, New South Wales, AustraliaGSK Investigational Site
Aug 16, 2017
Pulmonary Disease, Chronic Obstructive Trial in Worldwide (FF/UMEC/VI, Inhaled Corticosteroid, LAMA)
Completed
- Pulmonary Disease, Chronic Obstructive
- FF/UMEC/VI
- +4 more
-
Aschaffenburg, Bayern, Germany
- +142 more
Aug 19, 2020
Rhinitis, Allergic, Perennial Trial in Worldwide (FF, Placebo)
Pulmonary Disease, Chronic Obstructive Trial in Norway, Sweden (GW685698/GW642444)
Completed
- Pulmonary Disease, Chronic Obstructive
-
Bergen, Norway
- +8 more
Oct 26, 2016
Asthma Trial in United States (Fluticasone furoate, Matching )
Completed
- Asthma
- Fluticasone furoate
- Matching placebo
-
Cypress, California
- +4 more
Feb 20, 2017